YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + Placebo

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Functional Dyspepsia

Conditions

Functional Dyspepsia

Trial Timeline

Oct 1, 2015 → Mar 16, 2017

About YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + Placebo

YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + Placebo is a phase 2 stage product being developed by Yuhan for Functional Dyspepsia. The current trial status is terminated. This product is registered under clinical trial identifier NCT02567578. Target conditions include Functional Dyspepsia.

What happened to similar drugs?

0 of 6 similar drugs in Functional Dyspepsia were approved

Approved (0) Terminated (1) Active (5)
🔄Imonogas + EspumisanJohnson & JohnsonPhase 3
🔄Linaclotide + PlaceboAbbViePhase 3
Gabapentin + PlaceboPfizerPhase 3
🔄Z-338 + PlaceboZeria PharmaceuticalPhase 3
🔄Acotiamide hydrochloride hydrate + PlaceboZeria PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02567578Phase 2Terminated